X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (487) 487
index medicus (440) 440
oncology (278) 278
hematology (209) 209
cancer (185) 185
female (168) 168
male (155) 155
rituximab (145) 145
advanced basic science (144) 144
non-hodgkins-lymphoma (142) 142
middle aged (140) 140
chemotherapy (136) 136
advanced follicular lymphoma (133) 133
adult (124) 124
aged (124) 124
animals (122) 122
advanced-stage (110) 110
antineoplastic agents - therapeutic use (107) 107
follicular lymphoma (101) 101
lymphomas (101) 101
immunotherapy (100) 100
treatment outcome (98) 98
care and treatment (89) 89
chronic lymphocytic-leukemia (89) 89
hematology, oncology and palliative medicine (83) 83
medicine, research & experimental (82) 82
phase-ii trial (81) 81
antineoplastic combined chemotherapy protocols - therapeutic use (80) 80
lymphoma (76) 76
cell biology (73) 73
b-cell lymphoma (72) 72
prognosis (69) 69
advanced solid tumors (68) 68
research (67) 67
antibodies, monoclonal - therapeutic use (66) 66
pharmacology & pharmacy (65) 65
therapy (65) 65
lymphoma, non-hodgkin - drug therapy (61) 61
anti-cd20 monoclonal-antibody (58) 58
health aspects (57) 57
non-hodgkin-lymphoma (57) 57
aged, 80 and over (56) 56
article (56) 56
survival (56) 56
open-label (55) 55
analysis (54) 54
disease-free survival (54) 54
immunology (54) 54
neoplasms - drug therapy (53) 53
t cells (53) 53
cyclophosphamide (52) 52
lymphoma, follicular - drug therapy (52) 52
apoptosis (50) 50
advanced melanoma (49) 49
drug therapy (48) 48
biochemistry & molecular biology (47) 47
progression-free survival (46) 46
antibodies, monoclonal, murine-derived (45) 45
antineoplastic agents - adverse effects (43) 43
transplantation (43) 43
1st-line treatment (42) 42
low-grade (42) 42
review (42) 42
clinical trials as topic (41) 41
non-hodgkin's lymphomas (40) 40
clinical trials (39) 39
medicine & public health (39) 39
randomized controlled-trial (39) 39
biotechnology & applied microbiology (38) 38
tumors (38) 38
antineoplastic agents - pharmacology (37) 37
neoplasm staging (36) 36
antineoplastic agents - administration & dosage (35) 35
bone-marrow-transplantation (35) 35
cell lung-cancer (35) 35
chemotherapy plus rituximab (34) 34
combined modality therapy (34) 34
survival rate (33) 33
term-follow-up (33) 33
dendritic cells (32) 32
neoplasms - therapy (32) 32
patients (31) 31
phase-i (31) 31
survival analysis (31) 31
trial (31) 31
acute myeloid-leukemia (30) 30
lymphoma, follicular - mortality (30) 30
monoclonal antibodies (30) 30
stem-cell transplantation (30) 30
antineoplastic combined chemotherapy protocols - administration & dosage (29) 29
in-vivo (29) 29
leukemia (29) 29
lymphoma, b-cell - drug therapy (29) 29
mice (29) 29
phase-ii (29) 29
radioimmunotherapy (29) 29
stem cells (29) 29
t-cells (29) 29
toxicity (29) 29
expression (28) 28
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PRESSE MEDICALE, ISSN 0755-4982, 07/2019, Volume 48, Issue 7-8, pp. 850 - 858
Follicular lymphoma, the second most common lymphoma, is characterized by its slow growth and is often considered incurable in advanced stages. Progresses in... 
1ST-LINE TREATMENT | ADVANCED-STAGE | TRANSLOCATION | MEDICINE, GENERAL & INTERNAL | CYCLOPHOSPHAMIDE | RITUXIMAB | VINCRISTINE | RISK | OPEN-LABEL | PHASE-3 | GENOME-WIDE ASSOCIATION
Journal Article
British Journal of Haematology, ISSN 0007-1048, 08/2019, Volume 186, Issue 4, pp. 513 - 523
Summary Recent advances in the treatment of follicular lymphoma (FL) have provided insight into molecular and biological influences on pathogenesis and... 
follicular lymphoma | treatment | prognosis | PLUS RITUXIMAB | AUTOLOGOUS TRANSPLANTATION | RANDOMIZED-TRIAL | OPEN-LABEL | PROGNOSTIC VALUE | METABOLIC TUMOR VOLUME | ADVANCED-STAGE | 1ST-LINE IMMUNOCHEMOTHERAPY | NON-HODGKIN-LYMPHOMA | POOLED ANALYSIS | HEMATOLOGY | Lymphomas | Toxicity | Pathogenesis | Lymphoma
Journal Article
Cancer, ISSN 0008-543X, 06/2018, Volume 124, Issue 12, pp. 2484 - 2487
Autologous transplantation and allogeneic transplantation remain important treatment options to consider for appropriate follicular lymphoma patients with... 
1ST-LINE TREATMENT | ADVANCED-STAGE | ONCOLOGY | HIGH-RISK | INDOLENT LYMPHOMA | PHASE-3 TRIAL | EARLY RELAPSE | NON-HODGKIN-LYMPHOMA | OPEN-LABEL | RANDOMIZED CONTROLLED-TRIAL | STEM-CELL TRANSPLANTATION | Autografts | Transplantation | Lymphomas | Transplants & implants | Lymphoma | Patients
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2014, Volume 32, Issue 28, pp. 3096 - 3102
Journal Article
TURKISH JOURNAL OF HEMATOLOGY, ISSN 1300-7777, 03/2019, Volume 36, pp. 21 - 25
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 14, pp. 1389 - 1390
Rituximab changed the treatment of patients with follicular lymphoma. When added to standard chemotherapy regimens, it increased the response rate and the... 
TRIAL | ADVANCED-STAGE | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | CYCLOPHOSPHAMIDE | RITUXIMAB | VINCRISTINE | CHOP | OPEN-LABEL | R-CVP | PHASE-3 | Lymphoma, Follicular | Immunosuppressive Agents | Antibodies, Monoclonal | Lymphomas | Research | Drug therapy | Anti-antibodies | CD20 antigen | Cytotoxicity | Immunoglobulins | Chemotherapy | Lymphoma
Journal Article
European Journal of Haematology, ISSN 0902-4441, 09/2019, Volume 103, Issue 3, pp. 152 - 163
Journal Article
Journal Article
BLOOD, ISSN 0006-4971, 07/2019, Volume 134, Issue 4, pp. 353 - 362
The SAKK 35/10 phase 2 trial, developed by the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group, compared the activity of rituximab vs... 
ADVANCED-STAGE | MAINTENANCE | MANTLE-CELL LYMPHOMAS | RESPONSE CRITERIA | RANDOMIZED PHASE-II | INDOLENT LYMPHOMA | NATURAL-KILLER-CELL | NON-HODGKIN-LYMPHOMA | OPEN-LABEL | HEMATOLOGY | SINGLE-AGENT RITUXIMAB | Clinical Medicine | Medical and Health Sciences | Hematology | Hematologi | Medicin och hälsovetenskap | Klinisk medicin | Cancer and Oncology | Cancer och onkologi
Journal Article
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, ISSN 0889-8588, 08/2019, Volume 33, Issue 4, pp. 627 - 627
Follicular lymphoma is the most common indolent lymphoma in the United States. In this review article, the authors discuss the different prognostic biomarkers... 
1ST-LINE TREATMENT | Prognosis | Unmet needs | INITIAL TREATMENT | RANDOMIZED-TRIAL | OPEN-LABEL | Management | TREATMENT POLICY | ADVANCED-STAGE | NATIONAL LYMPHOCARE | ONCOLOGY | BENDAMUSTINE PLUS RITUXIMAB | Follicular lymphoma | NON-HODGKIN-LYMPHOMA | HEMATOLOGY | DETUDE DES LYMPHOMES
Journal Article
Current Treatment Options in Oncology, ISSN 1527-2729, 7/2015, Volume 16, Issue 7, pp. 1 - 13
The optimal initial treatment of follicular lymphoma (FL) is not known, and initial management of patients varies considerably between providers and... 
Follicular lymphoma | Rituximab | Watch and wait | Oncology | Initial therapy | Medicine & Public Health | LOW-TUMOR-BURDEN | NATURAL-KILLER-CELL | ADVANCED-STAGE | B-CELL LYMPHOMA | PHASE-II TRIAL | ONCOLOGY | GENE-EXPRESSION | NON-HODGKINS-LYMPHOMA | TERM-FOLLOW-UP | RITUXIMAB ERA | Care and treatment | Lymphomas | Research | Health aspects | Immunotherapy
Journal Article